Shanade Dunn
Postdoctoral Fellow
Wellcome Trust Sanger Institute in collaboration with AstraZeneca
Check out the incredible speaker line-up to see who will be joining Shanade .
Download The Latest AgendaDay One
Wednesday, May 17th, 2017
1:50 PM Using CRISPR screening to identify the genes involved in resistance and sensitisation to PI3K pathway inhibitors in breast cancer
- Understand how CRISPR screening can be used to identify resistant and sensitive genes related to the P13k pathway
- Learn what the screening data has shown and how the project is already achieving success
- Plan your CRISPR screening technique around the challenges uncovered and overcome in this project